All Stories

  1. Defining Important Aspects of Repigmentation in Vitiligo: Insights From Patients' Perspectives
  2. Bullous pemphigoid outcome measurement: a scoping review of outcome heterogeneity and trends in clinical research of treatments
  3. Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study
  4. Core outcome domain sets for clinical trials in epidermolysis bullosa — a COSEB protocol to achieve consensus on “what” to measure
  5. Mucous Membrane Pemphigoid Outcome Measurement in Clinical Research: A Scoping Review
  6. Navigating challenges in clinical trials for bullous pemphigoid and pemphigus: learnings from the clinical trial graveyard and an international expert survey
  7. Measuring health-related quality of life in patients with peripheral vascular malformations with PROMIS® computerized adaptive tests
  8. Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions
  9. A Quality Analysis of the Measurement Properties of the Clinician-Reported Outcome Measures for Vitiligo and of the Studies Assessing Them: A Systematic Review
  10. The Efficacy and Safety of Combining Phototherapy and Topicals in the Treatment of Atopic Eczema: A Systematic Review of the Current Evidence
  11. Approved systemic drugs needed for dermatosis like alopecia areata, hidradenitis and vitiligo: A SPIN‐FRT evaluation
  12. The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema
  13. The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review
  14. Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting
  15. Expanding the molecular and clinical spectrum of autosomal recessive congenital ichthyosis caused by pathogenic variants in NIPAL4 and PNPLA1 and evaluation of novel therapeutic interventions
  16. Reporting of Harmonising Outcome Measures for Eczema (HOME) core outcome set instruments in randomized clinical trials for systemic treatments in atopic dermatitis
  17. The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study
  18. Effectiveness and patient satisfaction of a Dutch patient decision aid for psoriasis – a pilot study
  19. Measurement instruments for the core outcome set of congenital melanocytic naevi and an assessment of the measurement properties according to COSMIN: a systematic review
  20. A core outcome domain set for clinical research on capillary malformations (the COSCAM project): an e-Delphi process and consensus meeting
  21. Appearance-related concerns and their impact on health-related quality of life in patients with peripheral vascular malformations
  22. Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review
  23. Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”
  24. Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2*
  25. Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project)
  26. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series
  27. The Selection Process for a Web-Based Application to Measure Patient-Reported Outcomes Following the Example of the TREAT NL Registry
  28. Work ability and quality of working life in atopic dermatitis patients treated with dupilumab
  29. Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals
  30. Learning from disease registries during a pandemic: Moving toward an international federation of patient registries
  31. Surgical Treatment of Peripheral Vascular Malformations: A Systematic Review and Meta-Analysis
  32. Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts
  33. Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey*
  34. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics
  35. Online decision aid for patients with psoriasis
  36. Responsiveness of quality of life measures in children with peripheral vascular malformations: The OVAMA project
  37. Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research*
  38. Phototherapy for atopic eczema
  39. Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*
  40. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations
  41. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
  42. Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach
  43. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations
  44. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry
  45. Outcome assessment in dermatology clinical trials and cochrane reviews: call for a dermatology‐specific outcome taxonomy
  46. International collaboration and rapid harmonization across dermatologic COVID-19 registries
  47. The current extent of and need for shared decision making in atopic dermatitis and psoriasis in the Netherlands: an online survey study amongst patients and physicians
  48. Immune-mediated inflammatory disease patients’ preferences in adverse drug reaction information regarding biologics
  49. Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic
  50. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis
  51. Generic outcome set for the international registry on Laser trEAtments in Dermatology (LEAD): a protocol for a Delphi study to achieve consensus on what to measure
  52. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis
  53. Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases
  54. Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative
  55. Outcomes and measurement instruments used in congenital melanocytic naevi research: A systematic review
  56. The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate‐to‐severe atopic eczema*
  57. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema ( RECAP )
  58. Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients
  59. Towards More Shared Decision Making in Dermatology: Develop­ment of Evidence-based Decision Cards for Psoriasis and Atopic Eczema Treatments
  60. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group
  61. Responsiveness of quality‐of‐life measures in patients with peripheral vascular malformations: the OVAMA project
  62. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema
  63. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data
  64. Protocol for the development of core set of domains of the core outcome set for patients with congenital melanocytic naevi (OCOMEN project)
  65. Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab
  66. Outcome measurement instruments for peripheral vascular malformations and an assessment of the measurement properties: a systematic review
  67. Finalizing the international core domain set for peripheral vascular malformations: the OVAMA project
  68. Navigating the landscape of core outcome set development in dermatology
  69. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period
  70. TRE atment of AT opic eczema ( TREAT ) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries
  71. Cochrane Reviews and Dermatological Trials Outcome Concordance: Why Core Outcome Sets Could Make Trial Results More Usable
  72. Highlights of the updated Dutch evidence‐ and consensus‐based guideline on psoriasis 2017
  73. Reversibility of alexithymia with effective treatment of moderate‐to‐severe psoriasis: longitudinal data from EPIDEPSO
  74. Relationship and probabilistic stratification of Eczema Area and Severity Index and objective Scoring Atopic Dermatitis severity scores for atopic dermatitis
  75. Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults
  76. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries
  77. Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis
  78. Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative
  79. Patient-Reported Outcomes of Bleomycin Sclerotherapy for Low-Flow Vascular Malformations and Predictors of Improvement
  80. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
  81. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial
  82. Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative
  83. By using a core outcome set we measure what matters to patients
  84. Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data
  85. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
  86. Development of an international core outcome set for peripheral vascular malformations: the OVAMA project
  87. Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study
  88. Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment
  89. Discrepancy between the clinical and histopathologic diagnosis of soft tissue vascular malformations
  90. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries
  91. How to write a Critically Appraised Topic: evidence to underpin routine clinical practice
  92. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council
  93. Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC
  94. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC
  95. Procollagen-3 N -terminal peptide measurements for the detection of liver fibrosis in methotrexate-treated patients with psoriasis: daily practice use and clinical implications
  96. The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries
  97. One-stop-shop with confocal microscopy imaging vs. standard care for surgical treatment of basal cell carcinoma: an open-label, noninferiority, randomized controlled multicentre trial
  98. Reporting of outcomes in randomised controlled trials on nail psoriasis; a Systematic Review
  99. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety
  100. Doing Good Research Is Difficult, Doing No Research Is More Difficult
  101. Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study
  102. Pregnancy and fetal outcomes after paternal exposure to azathioprine, methotrexate or mycophenolic acid: a critically appraised topic
  103. Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
  104. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement
  105. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries
  106. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study
  107. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial
  108. Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries
  109. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
  110. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field
  111. Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review
  112. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review
  113. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
  114. Global Allergy Forum and 3rd Davos Declaration 2015
  115. Intralesional Bleomycin Injections for Vascular Malformations
  116. Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation
  117. Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults
  118. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC
  119. Diphencyprone treatment in patients with alopecia areata
  120. The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial
  121. In vivo confocal microscopy of basal cell carcinoma: a systematic review of diagnostic accuracy
  122. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting
  123. Clearing up misunderstandings around core outcomes for atopic dermatitis
  124. Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis
  125. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres
  126. Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
  127. A national study on adherence to a basal cell carcinoma guideline; development of a tool to assess guideline adherence
  128. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal
  129. Health-related Quality of Life in Patients with Cutaneous Rosacea: A Systematic Review
  130. The Harmonizing Outcome Measures for Eczema (HOME) Roadmap: A Methodological Framework to Develop Core Sets of Outcome Measurements in Dermatology
  131. The IL-17A-Producing CD8 + T-Cell Population in Psoriatic Lesional Skin Comprises Mucosa-Associated Invariant T Cells and Conventional T Cells
  132. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)
  133. Combined Use of Systemic Agents for Psoriasis
  134. Prospective registration of clinical trials published in the B ritish J ournal of D ermatology
  135. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials
  136. An increased risk of non‐melanoma skin cancer during TNF‐inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease‐related factors
  137. Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR + ILC3 in Lesional Skin and Blood of Psoriasis Patients
  138. Prioritizing dermatoses: rationally selecting guideline topics
  139. Critically Appraised Topics in the British Journal of Dermatology : response from Jonathan Batchelor and Phyllis Spuls, section editors for BJD 's ‘Put...
  140. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single‐centre database analysis
  141. Treatment of Psoriasis
  142. Evaluation of a Tertiary Teledermatology Service Between Peripheral and Academic Dermatologists in The Netherlands
  143. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research
  144. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review
  145. Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis
  146. Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation
  147. Comment on ‘Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study’
  148. The European treatment of severe atopic eczema in children taskforce (TREAT) survey
  149. Accuracy and reliability of teledermatoscopy with images taken by general practitioners during everyday practice
  150. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries
  151. House dust mite reduction in the management of atopic dermatitis. A critically appraised topic
  152. Interventions for nail psoriasis
  153. The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: study protocol for a multicenter randomized controlled trial
  154. Measurement Properties of Outcome Measures for Vitiligo
  155. The prevalence of thyroid disease in patients with vitiligo: a systematic review
  156. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal
  157. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting
  158. Health-Related Quality-of-Life Assessment in Dermatologic Practice: Relevance and Application
  159. Response to a randomized trial of methotrexate vs. azathioprine for severe atopic eczema: a critical appraisal
  160. Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies
  161. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review
  162. Teledermatology applied following patient selection by general practitioners in daily practice improves efficiency and quality of care at lower cost
  163. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men
  164. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference
  165. A randomized trial of methotrexate versus azathioprine for severe atopic eczema
  166. A randomized comparison of excimer laser versus narrow‐band ultraviolet B phototherapy after punch grafting in stable vitiligo patients
  167. Survival in cancer patients hospitalized for psoriasis: a commentary
  168. Prospective comparison of three guideline development methods for treatment of actinic keratosis
  169. Off-label Use of Azathioprine in Dermatology
  170. Validation and refinement of the Millennium Criteria for atopic dermatitis
  171. Etanercept
  172. On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges
  173. A pilot study on tertiary teledermatology: feasibility and acceptance of telecommunication among dermatologists
  174. Evaluation of and Perspectives on Guidelines: What Is Important?
  175. Off-label use of efalizumab in dermatology
  176. Definition of treatment goals for moderate to severe psoriasis: a European consensus
  177. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept
  178. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot
  179. How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review
  180. Is there a rural/urban gradient in the prevalence of eczema? A systematic review
  181. Atopic eczema or atopiform dermatitis
  182. Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis
  183. Tertiary Teledermatology: A Systematic Review
  184. Experience with biologics for psoriasis in daily practice: switching is worth a try
  185. The burden of vitiligo: Patient characteristics associated with quality of life
  186. The Misperception That Clinical Trial Data Reflect Long-term Drug Safety
  187. A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: ‘AGREE-ing’ on a common base for European evidence-based psoriasis treatment guidelines
  188. Interventions for nail psoriasis
  189. National Registries of Systemic Treatment for Psoriasis and the European ‘Psonet’ Initiative
  190. STROBE
  191. Topical treatments in psoriasis: today and tomorrow
  192. Controversies in Atopic Dermatitis
  193. Clinical Differences between Atopic and Atopiform Dermatitis
  194. A Review of the Literature for Nail Psoriasis
  195. Retrospective study of the efficacy of narrowband UVB and acitretin
  196. Nonsurgical Repigmentation Therapies in Vitiligo
  197. A systematic review of five systemic treatments for severe psoriasis: Reply
  198. A systematic review of five systemic treatments for severe psoriasis
  199. Treatment of generalized bullous pemphigoid with topical corticosteroids.